In the first two quarters of 2012, there have been 12 approvals (NME and biologics) compared with 30 for 2011. The appovals of two obesity drugs, Qsymia and Belviq, a plant produced replacement enzyme for Gaucher's disease, Elelyso, and a PET imaging agent for Alzheimer's, Amyvid, were of note. Sodium glucose transporter 2 inhibitors continue to impress in the clinic. But trials of Pfizer's flagship Alzheimer's therapy bapineuzumab were finally suspended.
Change history
07 December 2012
In the version of the article originally published, the Thrombogenics drug Jetrea (recombinant microplasmin) was listed in “Notable upcoming regulatory decisions” as indicated for thyroid cancer. It should have read vitreomacular adhesion. The error has been corrected in the HMTL and PDF versions of the article.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
DeFrancesco, L. Drug pipeline: Q212. Nat Biotechnol 30, 817 (2012). https://doi.org/10.1038/nbt.2359
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2359
This article is cited by
-
Erratum: Drug pipeline: Q212
Nature Biotechnology (2012)
